Analysis of the Clinical Efficacy of Minocycline in the Treatment of Diabetic Retinopathy

Abstract

Song et al.: Minocycline Efficacy in the Treatment of Diabetic Retinopathy Minocycline has been proven to reduce oxidative stress. This article further explores the safety and clinical efficacy of minocycline in the treatment of diabetic retinopathy. Selected 60 patients with diabetic retinopathy admitted to our hospital and divided them into two groups, observation group (30 cases) and control group (30 cases) randomly. Both groups received conventional treatment. Then treated control group with calcium dobesilate capsule and rosuvastatin calcium tablet. As well as the same drugs in control group, observation group received minocycline and the treatment period was 60 d. Compared visual acuity score, diabetic retinopathy stage, retinal neovascularization fluorescein leakage area, incidence of complications and adverse drug reactions with both groups after treatment. The vision improvement of observation group was remarkably higher than control group (p<0.05); The incidence of retinopathy stage III in control group was 36.7 %, which was higher than 13.3 % of observation group (p<0.05); After treatment, the retinal neovascularization fluorescein leakage area decreased to 241.3±12.44 mm 2 and 249.3±16.12 mm 2 , respectively; The occurrence rate of complications in observation group was 30 %, while in control group was 56.7 %; The incidence of adverse drug reactions in both groups was basically similar (p>0.05). Minocycline has a definite effect on patients with diabetic retinopathy. It can improve the vision of diabetic retinopathy patients; effectively reduce the stages of diabetic retinopathy, the leakage area of fluorescein in retinal neovascularization and the occurrence of related complications. It has no obvious adverse reactions and is worthy of clinical promotion.

M1 Microglia-derived Exosomes Promote Activation of Resting Microglia and Amplifies Proangiogenic Effects through Irf1/miR-155-5p/Socs1 Axis in the Retina

“…The factors involved in angiogenesis, Sdf1 and Cxcr4, were strongly expressed, and proliferation of endothelial cells was observed in the retina after treatment with M1 microglial exosomes (Figure 6A-B). Minocycline, an inhibitor of microglial activation, significantly alleviated the increase in endothelial cells induced by M1 microglial exosomes (Figure 6C-E) [44,45,54]. Thus, we provide evidence, for the first time, that M1 microglial exosomes eventually cause abnormal endothelial cell proliferation in the retina, a fundamental early step in the angiogenic response [31], and this process is based on retinal inflammation, which plays a critical role in most neovascular ocular diseases [12].…”